¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"risk benefit analysis"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
À̰ÍÀ» ¿øÇϼ̽À´Ï±î?
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • risk assessment
    À§ÇèµµÆò°¡
  • risk difference
    À§ÇèµµÂ÷ÀÌ
  • risk factor
    À§ÇèÀÎÀÚ
  • risk management
    À§Çèµµ°ü¸®
  • risk marker
    À§ÇèÇ¥ÁöÀÚ
  • risk ratio
    À§Çèºñ
  • antigen analysis
    Ç׿øºÐ¼®
  • arterial blood gas analysis
    µ¿¸ÆÇ÷°¡½ººÐ¼®
  • activation analysis
    Ȱ¼ºÈ­ºÐ¼®, ¹æ»çÈ­ºÐ¼®
  • age-period cohort analysis
    ¿¬·É±â°£ÄÚȣƮºÐ¼®
  • analysis
    ºÐ¼®
  • birth cohort analysis
    Ãâ»ýÄÚȣƮºÐ¼®
  • clinical decision analysis
    ÀÓ»óÀÇ»ç°áÁ¤ºÐ¼®
  • clonal analysis
    Ŭ·ÐºÐ¼®
  • cluster analysis
    ¹«¸®ºÐ¼®
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • meta-analysis
    ¸ÞŸºÐ¼®
  • self-analysis
    ÀÚ±âºÐ¼®
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • high risk group
    °íÀ§Çèµµ±º
  • lifetime risk
    Æò»ýÀ§Çèµµ
  • multiple risk
    ´ÙÁßÀ§Çèµµ
  • risk management
    À§Çèµµ°ü¸®
  • risk marker
    À§Ç赵ǥÁö
  • time dependent relative risk model
    ½Ã°£ÀÇÁ¸»ó´ëÀ§Çè¸ðµ¨
  • operative risk
    ¼ö¼úÀ§Çèµµ
  • physical hazard risk
    ¹°¸®ÀûÀ¯ÇØÀ§Çèµµ
  • population attributable risk
    ÀϹÝÀα¸±â¿©À§Çèµµ
  • risk
    À§Çè, À§Çèµµ
  • radiation risk
    ¹æ»ç¼±À§Çèµµ
  • recurrence risk
    Àç¹ßÀ§Çèµµ
  • relative risk
    ºñ±³À§Çèµµ
  • risk ratio
    À§Çèµµºñ
  • surgical risk
    ¼ö¼úÀ§Çèµµ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • Data analysis
    Á¤º¸ºÐ¼®
  • Decision analysis
    °áÁ¤ºÐ¼®
  • activation analysis
    Ȱ¼ºÈ­ºÐ¼®(¡­ÝÂà°), ¹æ»çÈ­(Û¯ÞÒûù)ºÐ¼®.
  • activation analysis
    ¹æ»çÈ­ºÐ¼®, Ȱ¼ºÈ­ºÐ¼®
  • amniotic fluid analysis
    ¾ç¼öºÐ¼®
  • analysis
    ºÐ¼®
  • analysis of variance technique
    ºÐ»ê±â¼úºÐ¼®
  • analysis, antigen
    Ç׿øºÐ¼®
  • frequency analysis
    Á֯ļöºÐ¼®
  • gas analysis
    °¡½ººÐ¼®.
  • gas analysis
    °¡½ººÐ¼®
  • gasometric analysis
    ±âüÁ¤·®ºÐ¼®.
  • gastric analysis
    À§¾×°Ë»ç(¡­ËþÞÛ).
  • gene analysis
    À¯ÀüÀںм®(¡­ÝÂà°).
  • gene analysis
    À¯ÀüÀںм®.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • radiation risk
    ¹æ»ç¼±À§ÇØ, ¹æ»ç¼± À§Çè
  • radiation risk coeffecient
    ¹æ»ç¼±À§ÇèÁö¼ö
  • recurrence risk
    Àç¹ßÀ§Çè
  • relative risk
    ºñ±³À§Çèµµ
  • relative risk
    ºñ±³À§Çèµµ(ËÓË´Ëô̴̬).
  • relative risk estimation
    »ó´ë(-Àû) À§Çèµµ ÃßÁ¤(õÏïÒ)
  • risk factor
    À§ÇèÀÎÀÚ
  • risk factors
  • risk management
    À§Çè°ü¸®.
  • surgical risk
    ¼ö¼úÀ§Çèµµ(¼ö¼úÀ§ÇèŹ).
  • time dependent relative risk model
    ½Ã°£ÀÇÁ¸¼º »ó´ëÀ§Çè¸ðµ¨
  • activation analysis
    ¹æ»çÈ­ºÐ¼®, Ȱ¼ºÈ­ºÐ¼®
  • activation analysis
    Ȱ¼ºÈ­ºÐ¼®(¡­ÝÂà°), ¹æ»çÈ­(Û¯ÞÒûù)ºÐ¼®.
  • amniotic fluid analysis
    ¾ç¼öºÐ¼®
  • analysis
    ºÐ¼®
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • ionic mobility analysis
    À̿ À̵¿µµ(ì¹ÔÑÓø) ºÐ¼®(ÝÂà°)
  • isoelectric analysis
    µîÀüºÐ¼®(Ôõï³ÝÂà°)
  • isotope dilution analysis
    µ¿À§¿ø¼Ò Èñ¼®ºÐ¼®(ÔÒêÈêªáÈýüà·ÝÂà°)
  • isotopic dilution analysis
    µ¿À§¿ø¼Ò Èñ¼®ºÐ¼®(ÔÒêÈêªáÈýüà·ÝÂà°)
  • kinetic analysis
    ¹ÝÀÀ¼ÓµµºÐ¼®(ÚãëëáÜÓøÝÂà°)
  • methylation analysis
    ¸Þƿȭ(ûù)ºÐ¼®(ÝÂà°)
  • mobility shift analysis
    À̵¿µµ(ì¹ÔÑÓø)¿Å±è ºÐ¼®(ÝÂà°)
  • moving boundary analysis
    À̵¿°æ°è ºÐ¼®(ì¹ÔÑÌÑÍ£ÝÂà°)
  • multiple inhibition analysis
    ´ÙÁß(Òýñì)ÀúÇØ ºÐ¼®(îÁúªÝÂà°)
  • nearest-neighbor base frequency analysis
    ÃÖ±ÙÁ¢ ¿°±â ºóµµºÐ¼®(õÌÐÎïÈç¤ÐñÞºÓøÝÂà°)
  • proximate analysis
    ±Ù»çºÐ¼®(ÐÎÞÄÝÂà°)
  • radioactive analysis
    ¹æ»ç¼º ºÐ¼®(Û¯ÞÒàõÝÂà°)
  • radiometric analysis
    ¹æ»ç¹ý ºÐ¼® (Û¯ÞÒÛöÝÂà°)
  • saturation analysis
    Æ÷È­ ºÐ¼®(øéûùÝÂà°)
  • volumetric analysis
    ºÎÇÇ ºÐ¼®(ÝÂà°)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 3 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • statistical analysis
    Åë°èÀûºÐ¼®
  • urine analysis
    ¿ä°Ë»ç
  • vector analysis
    ¹éÅͺм®
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
RR radiation reaction; radiation response; rate ratio; rational recovery [group]; recovery room; relati...
MEDPAR Medical Provider Analysis and Review; Medicare Provider Analysis and Review
MRA magnetic resonance angiography; main renal artery; marrow repopulation activity; medical record anal...
GLOBE Global Learning and Observations to Benefit the Environment
ADB accidental death benefit
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
ARIC Atherosclerosis Risk In Communities
AR Attributable Risk
BRFSS Behavioral Risk Factor Surveillance System
CVRF Cardiovascular risk factor
CRIB Clinical Risk Index for Babies
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • binding displacement analysis
    °áÇÕ º¯À§ ºÐ¼®
  • bite analysis
    ±³ÇÕ ºÐ¼®
    ±³ÇÕ°£ °ü°è³ª ±× Ç¥½Ã¸¦ ºÐ¼®ÇÏ´Â °Í.
  • case analysis
    Áõ·Ê ºÐ¼®
  • character analysis
    ¼º°Ý ºÐ¼®
  • cluster analysis
    ±ÕÁÖ±º ºÐ¼®
  • computerized image analysis
    ÄÄÇ»ÅÍ ¿µ»ó ºÐ¼®
  • continuous flow blood analysis
    Áö¼Ó¼º À¯µ¿ Ç÷¾× ºÐ¼®
  • dietary analysis
    ½ÄÀÌ ºÐ¼®
  • dynamic mechanical analysis
    µ¿Àû ±â°èÀû ºÐ¼®
  • ego analysis
    ÀÚ¾Æ ºÐ¼®
  • electron beam microporbe analysis
    ÀüÀÚ±¤ ¹Ì¼¼ Žħ ¿ä¼Ò ºÐ¼®, ÀüÀÚ±¤ ¹Ì¼¼ Žħ ºÐ¼®
  • electron microprobe analysis
    ÀüÀÚ ¹Ì¼¼ Žħ
  • elementary analysis
    ¿ø¼Ò ºÐ¼®
    À¯±â È­ÇÕ¹°¿¡ ÇÔÀ¯µÇ¾î ÀÖ´Â ¿ø¼ÒÀÇ Á¾·ù¸¦ °áÁ¤Çϰųª, ºñÀ²À» °áÁ¤ÇÏ´Â ºÐ¼® ¹æ¹ý. ÀüÀÚ¸¦ Á¤¼º ¿ø¼Ò ºÐ¼®, ÈÄÀÚ¸¦ Á¤·® ¿ø¼Ò ºÐ¼®À̶ó°í ÇÑ´Ù. Á¤¼º ¿ø¼Ò ºÐ¼®, Áï ¿ø¼Ò °ËÃâ¹ý¿¡¼­´Â À¯±â È­ÇÕ¹°À» ±¸¼ºÇϰí ÀÖ´Â °¢ ¿ø¼Ò¿¡ µû¶ó ¿©·¯ °¡Áö ¹æ¹ýÀÌ »ç¿ëµÇÁö¸¸, ¸ðµÎ À¯±â È­ÇÕ¹°À» ºÐÇØÇÏ¿© °£´ÜÇÑ ¹«±â È­ÇÕ¹°·Î °ËÃâÇÑ´Ù. Á¤·® ¿ø¼Ò ºÐ¼®, Áï ÇÔÀ¯·®À» °áÁ¤ÇÏ´Â ¹æ¹ý¿¡´Â äÃëÇÏ´Â ½Ã·áÀÇ ¾ç¿¡ µû¶ó¼­ »ó·®¹ý
  • Enlow Analysis
    ¿£·Î¿ì ºÐ¼®
  • frequency analysis
    ÁÖÆÄ ¼ö ºÐ¼®
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
risk of recurrence In medical genetics, the chance that a genetic (inherited) disease present in a family will recur in that family. The concept in general medicine means the chance that an illness we come back again.
(12 Dec 1998)
risk patient Patient who is at risk, because of his/her behaviour or because of the type of person he/she is.
(18 Nov 1997)
risk reduction Techniques used to reduce your chances of getting a certain cancer. For example: reducing your dietary fat may help prevent breast cancer.
(09 Oct 1997)
risk-taking Undertaking a task involving a challenge for achievement or a desirable goal in which there is a lack of certainty or a fear of failure. It may also include the exhibiting of certain behaviours whose outcomes may present a risk to the individual or to those associated with him or her.
(12 Dec 1998)
competing risk An event that removes a subject from being at risk for an outcome under investigation.
(05 Mar 2000)
pregnancy, high-risk Pregnancy in which the mother and/or foetus are at greater than normal risk of morbidity or mortality. Causes include lack of adequate prenatal care, previous obstetrical history, pre-existing maternal disease or pregnancy-induced disease, and multiple gestation, as well as advanced maternal age.
(12 Dec 1998)
health risk assessment Method of describing an individual's chance of falling ill or dying of a specified condition, based on actuarial calculations that allow for known exposure to risk; expressed as expected age at which death or disease will occur, and intended as a way of drawing an individual's attention to the probable consequences of risk behaviour.
(05 Mar 2000)
oesophageal carcinoma risk factors <radiology> P Plummer-Vinson Web, A achalasia, alcohol, B Barrett oesophagus, S stricture, T tylosis, tobacco see: oesophageal carcinoma
(12 Dec 1998)
thyroid carcinoma risk factors <radiology> Increased risk of malignancy: young female, male, history of radiation to head or neck, hard lesion, other neck masses, no shrinkage on TSH, family hx of thyroid carcinoma see: thyroid carcinoma
(12 Dec 1998)
empiric risk The chance that a disease will occur in a family based upon experience (past history, medical records, etc.) rather than theory.
(12 Dec 1998)
accumulation analysis A technique in which an intermediate of a metabolic pathway accumulates due to selective inhibition of a particular step in that pathway or in a mutant that is deficient in a certain step. The intermediate is then isolated, analyzed, and identified.
(05 Mar 2000)
activation analysis <radiobiology> Method for identifying and measuring chemical elements in a sample of material. Sample is first made radioactive by bombardment with neutrons, charged particles, or gamma rays.
Newly formed radioactive atoms in the sample then give off characteristic radiations (such as gamma rays) that tell what kinds of atoms are present, and how many.
(09 Oct 1997)
actuarial analysis The application of probability and statistical methods to calculate the risk of occurrence of any event, such as onset of illness, recurrent disease, hospitalization, disability, or death. It may include calculation of the anticipated money costs of such events and of the premiums necessary to provide for payment of such costs.
(12 Dec 1998)
amino acid analysis Determination and identification of amino acid content of a macromolecule, identification of a specific amino acid in macromolecules, often a mutated protein, identification and quantitation of amino acid content in blood plasma or urine; a key diagnostic aid.
(05 Mar 2000)
analysis <technique> The separation into component parts or elements, the act of determining the component parts of a substance.
Origin: Gr. Lysis = dissolution
(18 Nov 1997)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • benefit
    ÀÌÀÍ;ÀºÇý;ÀºÀü;±âºÎ±Ý;Èñ»ç;ÀÚ¼± ÈïÇà-ÀÌÀÍÀ» ÁÖ´Ù;µµ¿òÀ» ¹Þ´Ù(profit)
  • benefit society
    °øÁ¦Á¶ÇÕ
  • child benefit
    (±¹°¡°¡ Áö±ÞÇÏ´Â)¾Æµ¿ ¼ö´ç
  • cost-benefit
    ºñ¿ë°ú ÆíÀÍÀÇ;ºñ¿ë ´ë ÆíÀÍÀÇ
  • death benefit
    (»ýº¸)»ç¸Á ±ÞºÎ±Ý
  • fringe benefit
    ºÎ°¡ ±ÞºÎ
  • injury benefit
    (¿µ)»êÀç º¸Çè±Ý(³ª¶ó°¡ ¸ÅÁÖ ÁöºÒ):
  • invalidity benefit
    (¿µ)(±¹¹Î º¸Çè¿¡ ÀÇÇÑ)Áúº´ ±ÞºÎ(IVB)
  • maternity benefit
    (±¹¹Î º¸ÇèÀÇ) Ãâ»ê ¼ö´ç
  • public benefit
    =PUBLIC GOOD
  • sick benefit
    Áúº´ ½Ç¾÷ ¼ö´ç
  • unemployment benefit
    ½Ç¾÷¼ö´ç
  • analysis
    ºÐÇØ
  • analysis
    ºÐ¼®;ÇØ¼®;ºÐÇØ
  • conformational analysis
    ¹èÁÂ ÇØ¼®
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á